- Home
- EVOK vs NCNA Comparison
EVOK vs NCNA Comparison
Compare EVOK & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- NCNA
- Stock Information
- Founded
- EVOK 2007
- NCNA 1997
- Country
- EVOK United States
- NCNA United Kingdom
- Employees
- EVOK N/A
- NCNA N/A
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- EVOK Health Care
- NCNA Health Care
- Exchange
- EVOK Nasdaq
- NCNA Nasdaq
- Market Cap
- EVOK 5.4M
- NCNA 15.4M
- IPO Year
- EVOK 2013
- NCNA 2017
- Fundamental
- Price
- EVOK $5.53
- NCNA $3.44
- Analyst Decision
- EVOK
- NCNA Buy
- Analyst Count
- EVOK 0
- NCNA 2
- Target Price
- EVOK N/A
- NCNA $5,000.00
- AVG Volume (30 Days)
- EVOK 476.4K
- NCNA 733.3K
- Earning Date
- EVOK 08-14-2025
- NCNA 08-20-2025
- Dividend Yield
- EVOK N/A
- NCNA N/A
- EPS Growth
- EVOK N/A
- NCNA N/A
- EPS
- EVOK N/A
- NCNA N/A
- Revenue
- EVOK $12,794,859.00
- NCNA N/A
- Revenue This Year
- EVOK $57.82
- NCNA N/A
- Revenue Next Year
- EVOK $59.12
- NCNA N/A
- P/E Ratio
- EVOK N/A
- NCNA N/A
- Revenue Growth
- EVOK 70.02
- NCNA N/A
- 52 Week Low
- EVOK $1.94
- NCNA $3.05
- 52 Week High
- EVOK $12.32
- NCNA $1,856.00
- Technical
- Relative Strength Index (RSI)
- EVOK 54.74
- NCNA 30.79
- Support Level
- EVOK $4.61
- NCNA $3.05
- Resistance Level
- EVOK $7.04
- NCNA $3.78
- Average True Range (ATR)
- EVOK 0.49
- NCNA 0.82
- MACD
- EVOK 0.03
- NCNA 0.11
- Stochastic Oscillator
- EVOK 37.86
- NCNA 5.61
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.